DSpace Repository

Prognostic significance of P53, Bcl-2, and fas expression in patients with primary gastrointestinal diffuse large B-cell lymphoma

Show simple item record

dc.contributor.author Çakmak, E.
dc.contributor.author Sarı, İsmail
dc.contributor.author Canoz, Ö.
dc.contributor.author Eser, B.
dc.contributor.author Altuntaş, F.
dc.contributor.author Çetin, M.
dc.contributor.author Ünal, A.
dc.date.accessioned 2019-08-16T13:19:11Z
dc.date.available 2019-08-16T13:19:11Z
dc.date.issued 2015
dc.identifier.issn 1300199X (ISSN)
dc.identifier.uri http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/10474
dc.description.abstract Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments. © 2015 by Erciyes University School of Medicine.
dc.language.iso English
dc.publisher AVES Ibrahim Kara
dc.relation.isversionof 10.5152/etd.2015.150001
dc.rights info:eu-repo/semantics/closedAccess
dc.subject Bcl-2
dc.subject Fas
dc.subject Lymphoma
dc.subject P53
dc.subject Prognosis
dc.subject biological marker
dc.subject bleomycin
dc.subject cisplatin
dc.subject cyclophosphamide
dc.subject cytarabine
dc.subject dexamethasone
dc.subject doxorubicin
dc.subject etoposide
dc.subject Fas antigen
dc.subject folinic acid
dc.subject methotrexate
dc.subject methylprednisolone
dc.subject prednisolone
dc.subject protein bcl 2
dc.subject protein p53
dc.subject vincristine
dc.subject adult
dc.subject aged
dc.subject Article
dc.subject cancer chemotherapy
dc.subject cancer prognosis
dc.subject clinical article
dc.subject electrocorticography
dc.subject female
dc.subject gastrointestinal disease
dc.subject human
dc.subject immunohistochemistry
dc.subject International Prognostic Index
dc.subject lactate dehydrogenase blood level
dc.subject large cell lymphoma
dc.subject male
dc.subject middle aged
dc.subject overall survival
dc.subject protein expression
dc.subject retrospective study
dc.subject treatment response
dc.title Prognostic significance of P53, Bcl-2, and fas expression in patients with primary gastrointestinal diffuse large B-cell lymphoma
dc.type Article
dc.relation.journal Erciyes Tip Dergisi
dc.identifier.volume 37
dc.identifier.issue 3
dc.identifier.startpage 102
dc.identifier.endpage 105
dc.relation.publicationCategory Uluslararası Hakemli Dergi
dc.identifier.index Scopus
dc.identifier.index WOS


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record